Anti-Mouse EpCAM (CD326) – Purified in vivo GOLD^TM Functional Grade

TE-71 thymic epithelial cell line

This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Liquid

Functional grade preclinical antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -70°C. Avoid Repeated Freeze Thaw Cycles.

Research Use Only

2-8°C Wet Ice

G8.8 activity is directed against mouse EpCAM (CD326) and does not recognize human or rat EpCAM.

Epithelial cell adhesion molecule (EpCAM; also known as CD326 or Tacstd1) is a 40 kDa type I transmembrane glycoprotein composed of an extracellular domain, single transmembrane domain, and the intracellular domain Ep1CD¹. EpCAM functions in cell adhesion, signaling, differentiation, migration, proliferation, formation and maintenance of organ morphology, and morphogenic movements during gastrulation. Additionally, EpCAM is essential for cell junctions; the AxxxG motif in the transmembrane domain of EpCAM associates directly with claudin-7, an important tight junction protein. EpCAM also suppresses or enhances E-cadherin function depending on the context of the interaction. Mutant animal models have been developed in mouse (at least four global EpCAM knockout types and one conditional knockout), zebrafish, and Xenopus.

Dysregulation and/or mutations are associated with congenital tufting enteropathy (CTE), which causes lethal diarrhea in newborns, cholestatic liver diseases, and cancer¹. EpCAM promotes the proliferation of tumors, is involved in tumorigenesis and metastasis, and EpCAM positive cells serve as cancer stem cells for various human cancers. Therapeutic approaches targeting EpCAM are under development to eliminate chemotherapeutic drug resistance in cancer stem cells by conjugating cancer stem cells targeting EpCAM aptamer with a chemotherapeutic drug. Additionally, EpCAM antibody sensitizes chemoresistant myeloid leukemia to innate immune cells, and EpCAM peptide-primed dendritic cell vaccinations exhibit anti-tumor immunity in hepatocellular carcinoma cells.

Monoclonal antibody G8.8 was raised against glycoconjugates isolated from the TE-71 mouse thymic epithelial cell line². Splenic cell suspensions were fused with X63-Ag8.653 cells and the resulting hybridomas were screened on frozen Balb/c thymus.

EpCAM is expressed in many epithelial tissues from very early embryos to adult animals and is a cell surface marker on various stem and progenitor cells. EpCAM is also an important carcinoma marker highly expressed on a variety of carcinomas, including epithelial tumors and acute myeloid leukemia. EpCAM is enriched in the basolateral membrane of mouse and human intestinal epithelium and is localized to tight junctions, adherens junctions, and the lateral membranes of epithelial cells lining the intestines.

LAIR-1 (CD305) and LAIR-2 (CD306)

1. Huang L, Yang Y, Yang F, et al. Int J Mol Med. 42(4):1771-1785. 2018.
2. Farr A, Nelson A, Truex J, et al. J Histochem Cytochem. 39(5):645-653. 1991.
3. Li H, Hsu HC, Wu Q, et al. Nat Commun. 5:4259. 2014.
4. Wang J, Wang D, Chu K, et al. Nat Commun. 10(1):4966. 2019.
5. Martínez LE, Garcia G Jr, Contreras D, et al. J Virol. 94(9):e00067-20. 2020.
6. Petersen B, Wolf M, Austermann J, et al. EMBO J. 32(1):100-111. 2013.
7. Snitow M, Lu M, Cheng L, et al. Development. 143(20):3733-3741. 2016.
8. Kazakevych J, Denizot J, Liebert A, et al. Genome Biol. 21(1):64. 2020.
9. Maaser K, Borlak J. Br J Cancer. 99(10):1635-1643. 2008.
10. Kuan II, Liang KH, Wang YP, et al. Sci Rep. 7:41852. 2017.
11. Kuroki S, Maeda R, Yano M, et al. Stem Cell Reports. 15(2):424-438. 2020.
12. Papadopoulou AS, Dooley J, Linterman MA, et al. Nat Immunol. 13(2):181-187. 2011.
13. Goldman O, Han S, Sourisseau M, et al. Cell Stem Cell. 12(6):748-760. 2013.
14. Shim EJ, Bang BR, Kang SG, et al. J Immunol. 191(5):2764-2770. 2013.
15. de Jong JH, Rodermond HM, Zimberlin CD, et al. Sci Rep. 2:271. 2012.
16. Liu Z, Guo W, Zhang D, et al. Sci Rep. 6:39808. 2016.
17. Freire T, Zhang X, Dériaud E, et al. Blood. 116(18):3526-3536. 2010.
18. Naus S, Blanchet MR, Gossens K, et al. Am J Respir Crit Care Med. 181(12):1318-1328.2010.
19. Cook BD, Liu S, Evans T. Blood. 16;117(24):6489-6497. 2011.
20. Krishnamurthy B, Chee J, Jhala G et al. Diabetes. 61(2):425-435. 2012.
21. El-Zaatari M, Kao JY, Tessier A, et al. PLoS One. 8(3):e58935. 2013.
22. Magness ST, Puthoff BJ, Crissey MA, et al. Am J Physiol Gastrointest Liver Physiol.305(8):G542-551. 2013.
23. Tata PR, Mou H, Pardo-Saganta A, et al. Nature. 503(7475):218-223. 2013.
24. Fischedick G, Wu G, Adachi K, et al. Stem Cell Res. 13(2):300-315. 2014.
25. Velardi E, Tsai JJ, Holland AM, et al. J Exp Med. 211(12):2341-2349. 2014.
26. Clatworthy MR, Aronin CE, Mathews RJ, et al. Nat Med. 20(12):1458-1463. 2014.
27. Thelemann C, Eren RO, Coutaz M, et al. PLoS One. 9(1):e86844. 2014.
28. Walmsley GG, Rinkevich Y, Hu MS, et al. Tissue Eng Part C Methods. 21(3):314-321. 2015.
29. Xia H, Ren X, Bolte CS, et al. Am J Respir Cell Mol Biol. 52(5):611-621. 2015.
30. Goto Y, Lamichhane A, Kamioka M, et al. Sci Rep. 5:15918. 2015.
31. Satoh R, Kakugawa K, Yasuda T, et al. PLoS Genet. 12(1):e1005776. 2016.
32. Shi Y, Wu W, Chai Q, et al. Nat Commun. 7:12369. 2016.
33. Cuccarese MF, Dubach JM, Pfirschke C, et al. Nat Commun. 8:14293. 2017.
34. Yamaji M, Jishage M, Meyer C, et al. Nature. 543(7646):568-572. 2017.
35. Lim JS, Ibaseta A, Fischer MM, et al. Nature. 545(7654):360-364. 2017.
36. Lopes N, Vachon H, Marie J, et al. EMBO Mol Med. 9(6):835-851. 2017.
37. Nikolaidis NM, Noel JG, Pitstick LB, et al. Proc Natl Acad Sci U S A. 114(32):E6613-E6622.2017
38. Koh AS, Miller EL, Buenrostro JD, et al. Nat Immunol. 19(2):162-172. 2018.
39. Lopes N, Charaix J, Cédile O, et al. Nat Commun. 9(1):1262. 2018.
40. Moretti FA, Klapproth S, Ruppert R, et al. Elife. 7:e35816. 2018.
41. Thilakasiri P, Huynh J, Poh AR, et al. EMBO Mol Med. 11(4):e9539. 2019.
42. Glal D, Sudhakar JN, Lu HH, et al. Front Immunol. 9:2522. 2018.
43. Wang X, Yang L, Wang YC, et al. Cell Res. 30(12):1109-1126. 2020.
44. Giraud J, Foroutan M, Boubaker-Vitre J, et al. Transl Oncol. 14(2):101001. 2021.
45. Goga A, Yagabasan B, Herrmanns K, et al. Nat Commun. 12(1):3339. 2021.
46. Mauduit O, Aure MH, Delcroix V, et al. Cell Rep. 39(2):110663. 2022.
47. Ferreirinha P, Pinheiro RGR, Landry JJM, et al. Development. 149(10):dev200513. 2022.